Assessing the Safety and Bioactivity of SG1002 in Heart Failure Patients

Heart Failure Clinical Trial

Official title:

A Randomised, Double-blinded, Placebo-controlled Study to Assess the Safety and Bioactivity of Sodium Polysulthionate (SG1002) in Heart Failure Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02278276
• Other study ID #: Sulfagenix-SG1002-002
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• First received: October 23, 2014
• Last updated: November 25, 2015
• Start date: April 2016
• Est. completion date: July 2018

Study information

• Verified date: November 2015
• Source: Sulfagenix Australia Pty Ltd.
• Contact: Tony Giordano, PhD
• Phone: 318-349-3851
• Email: tgiordano[@]sulfagenix.com
• Is FDA regulated: No
• Health authority: Australia: Human Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and benefits of SG1002, including overcoming deficits in circulating hydrogen sulfide and nitrite found in heart failure patients, with secondary endpoints focused on improving clinical endpoints.

Description:

This will be a 3 month, placebo controlled double blind study, to determine whether 800 mg SG1002 given twice daily will be safe and will improve circulating levels of hydrogen sulfide and/or nitrite in heart failure subjects. In addition, secondary endpoints such as 6 minute walk distance, Minnesota heart failure questionnaire, biomarkers of inflammation and oxidative stress and cardiac remodeling will be assessed.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: July 2018
• Est. primary completion date: April 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 35 Years to 85 Years

Eligibility

Inclusion Criteria:

• symptomatic heart failure, with New York Heart Association (NYHA) classification of stage III;

• be ambulatory;

• have left ventricular ejection fraction less than 40% within 6 months of screening;

• have heart failure that has been stable for the previous 3 months (defined by no change in baseline therapy or symptoms of heart failure for the previous 3 months)(changes in diuretics are permitted);

• if female, be either post-menopausal or surgically sterilised or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) from signing of the informed consent form though to the Final Visit/Early Termination Visit; and

• be willing and able to provide written informed consent.

Exclusion Criteria:

• pregnant or breastfeeding;

• has had any of the following within 3 months prior to screening: myocardial infarction, unstable angina, cerebrovascular accident, percutaneous coronary intervention, open heart surgery, cardiac resynchronisation therapy (CRT) or transient ischaemic attack (TIA);

• has serious cerebrovascular disease in the opinion of the PI;

• is unable to walk without the assistance of another person;

• has primary lung disease that is the major contributor to current symptom status;

• is currently participating in another interventional clinical study, or has participated in one within 30 days prior to screening;

• has an inability to speak English (due to need to administer standardised English-language questionnaires);

• has current symptomatic hypotension (defined as systolic blood pressure (SBP) = 90 mmHg or diastolic blood pressure (DBP) = 40 mmHg);

• has poorly controlled hypertension (defined as SBP = 160 mmHg or DBP = 100 mmHg) despite therapy;

• will have percutaneous coronary intervention or open heart surgery within 3 months of the screening visit;

• has serious liver disease;

• has poorly controlled diabetes (defined as HbA1c > 10.0 %);

• has hypersensitivity to sulfur or related compounds;

• uses sulfur containing products or supplements, such as dimethyl sulfoxide (DMSO) or methylsulfonylmethane (MSM);

• has renal insufficiency defined as eGFR < 30 mL/minute/1.73 m2 (Modification of Diet in Renal Disease Study MDRD);

• has a life expectancy of less than 6 months;

• has active malignancy requiring active anti-neoplastic therapy that will, in the opinion of the Investigator, interfere with study treatment or participation. (Stable basal cell skin cancer and cancers being treated solely with hormonal therapy are allowed);

• has evidence of drug or alcohol abuse within the past 3 years;

• has any other chronic illness that may, in the opinion of the Investigator, increase the risks associated with this trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Heart Failure

Intervention

Drug:
• sodium polysulthionate
Bioavailable composition of a-sulfur
• Placebo
400 mg capsules containing placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sulfagenix Australia Pty Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite measure using adverse events, clinical laboratory tests, vital signs and ECGs		3 month	Yes
Primary	Changes in blood levels of hydrogen sulfide and nitrite in the SG1002 group measured by comparing the area under the curves after administration of the first dose and baseline levels of each at the first visit versus the final visit.	Demonstration of bioactivity as evidenced by increases in circulating levels of hydrogen sulfide and/or one or more nitric oxide metabolites, including nitrite, S-nitrosothiols and guanosine cyclic monophosphate levels as assessed by comparing AUC between placebo and SG1002 groups and by comparing baseline levels pre-administration at the start of the study to preadministration at the conclusion of the study.	3 months	No
Secondary	Heart function	A change from baseline to 13 weeks in BNP levels or cardiac remodeling as assessed by echocardiograms	3 months	No
Secondary	Body mass and waste circumference	A change from baseline to 13 weeks in waist circumference and body mass index	3 months	No
Secondary	Biomarkers of inflammation and oxidative stress	A change from baseline to 13 weeks in biomarkers of inflammation, C-reactive Protein (CRP) and interleukin 6 (IL6) and oxidative stress, oxidized LDL (oxLDL) and ratio of reduced glytathione (GSH) to oxidized glutathione (GSSG)	3 months	No
Secondary	Walking distance in 6 minute	A change from baseline to 13 weeks in the distance walked in 6 minutes	3 months	No
Secondary	Minnesota Heart Failure Questionnaire	A change from baseline to 13 weeks in quality of life as assessed by Minnesota Heart Failure Questionnaire	3 months	No